The Alliance for Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Med, took place in Barcelona back in April. ABL Biomanufacturing - a pure play Contract Development and Manufacturing ...

Oxford Bio’s recently-appointed chief executive, Dr Frank Mathias, said buying ABL would contribute to the company’s strategy to transition to a pure-play CDMO focusing on the cell and gene ...

Abl tyrosine kinase activity was determined using a synthetic peptide (EAIYAAPFAKKK) as substrate. The activities of Lyn and Csk tyrosine kinases were assayed using a Src substrate peptide ...

ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7 ...